IRVINE, Calif., Nov. 17, 2005 (PRIMEZONE) -- "Yet another head turning breakthrough has occurred in the stem cell research area," stated SmallCap Sentinel analyst D.R. Clark. "A London research team has been able to create cartilage from stem cells, a development that would seem to be the first of its kind and yet another testament to the seemingly boundless applications for stem cells."
Cartilage is the dense connective tissue usually found between bones to allow the smooth movement of joints. The research provides hope that replacement cartilage might one day be grown for transplantation for a number of problems, including sports injuries and hip replacement surgery, the researchers were quoted as saying in an international report.
"The announcement comes at a time when trading patterns for many stem cell related public companies have been mercurial at best," Clark added. "It's interesting to note that stem cell companies don't seem to be benefiting from blockbuster announcements within the industry. Buyers of stem cell related equities right now are in essence, getting these news events for free."
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will address New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European research and development with Western management, StemCells Inc. (Nasdaq:STEM) which recently announced success in enabling once paralyzed mice to walk again, Aastrom Biosciences Inc. (Nasdaq:ASTM) and Geron Corp. (Nasdaq:GERN).
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen-hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.